Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 9/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 9/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 9/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538127 | 0.74 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL6651275 | 0.73 | CYP1A2 (0.41) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL4504196 | 0.72 | CDK4 (0.41) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL4506826 | 0.72 | MAPK10 (0.54) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL1760511 | 0.72 | IDO1 (0.37) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL3190092 | 0.70 | AHR (0.45) | KIF11 | |
| SCHEMBL23412386 | 0.69 | F12 (0.46) | ADRA2AADRA2BADRA2CKIF11 | |
| SCHEMBL1501931 | 0.69 | IDO1 (0.59) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL4144107 | 0.68 | CYP3A4 (0.47) | KIF11 | |
| SCHEMBL31531653 | 0.68 | CYP3A4 (0.47) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595966-B1 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | BTG INT LTD (GB) | 2020-10-28 | — | — | EP | claimed |
| US-8809526-B2 | Synthesis of cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | claimed |
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | claimed |
| EP-2595966-A2 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | Onyx Pharmaceuticals, Inc. (US) | 2013-05-29 | — | — | EP | claimed |
| WO-2012011939-A2 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | ONYX PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | claimed |
| EP-0758328-B1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BTG INT LTD (GB) | 2003-07-16 | — | — | EP | claimed |
| US-5747499-A | CYCLOPENTAQUINAZOLINE COMPOUNDS CYCLOPENTAQUINAZOLINE COMPOUNDS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1998-05-05 | — | — | US | claimed |
| EP-0758328-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BTG INTERNATIONAL LIMITED (GB) | 1997-02-19 | — | — | EP | claimed |
| WO-1995030673-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-11-16 | — | — | WO | claimed |
| US-12435066-B2 | Substituted tricyclic compounds | LUPIN LIMITED (IN) | 2025-10-07 | — | — | US | disclosed |
| US-20230013778-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LIMITED (IN) | 2023-01-19 | — | — | US | disclosed |
| EP-2595966-B1 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | BTG INT LTD (GB) | 2020-10-28 | — | — | EP | disclosed |
| EP-2655398-B1 | EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT | BTG INT LTD (GB) | 2016-08-24 | — | — | EP | disclosed |
| US-8809526-B2 | Synthesis of cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-5747499-A | CYCLOPENTAQUINAZOLINE COMPOUNDS CYCLOPENTAQUINAZOLINE COMPOUNDS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1998-05-05 | — | — | US | disclosed |
| US-5747499-A | CYCLOPENTAQUINAZOLINE COMPOUNDS CYCLOPENTAQUINAZOLINE COMPOUNDS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1998-05-05 | — | — | US | disclosed |
| EP-0758328-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BTG INTERNATIONAL LIMITED (GB) | 1997-02-19 | — | — | EP | disclosed |
| EP-0758328-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BTG INTERNATIONAL LIMITED (GB) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995030673-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-11-16 | — | — | WO | disclosed |
| WO-1995030673-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013778-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | SOS1, RSU1, KSR1 | ADRA2A 3470/4885ADRA2B 3158/4885ADRA2C 3344/4885 |
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | GLUL, QPCT, ASNS | ADRA2A 2174/4885ADRA2B 3133/4885ADRA2C 2375/4885 |
| US-12435066-B2 | Substituted tricyclic compounds | SOS1, RSU1, KSR1 | ADRA2A 3470/4885ADRA2B 3158/4885ADRA2C 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.